CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

20181,085 citationsJournal Articlebronze Open Access

Authors

Ranjana H. Advani · Stanford University

Ian W. Flinn · Tennessee Oncology

Leslie Popplewell · City of Hope

Andres Forero · University of Alabama at Birmingham

Nancy L. Bartlett · Washington University in St. Louis

Nilanjan Ghosh · Levine Cancer Institute

Justin Kline ·

Abstract

The macrophage checkpoint inhibitor 5F9 combined with rituximab showed promising activity in patients with aggressive and indolent lymphoma. No clinically significant safety events were observed in this initial study. (Funded by Forty Seven and the Leukemia and Lymphoma Society; ClinicalTrials.gov number, NCT02953509 .).

Topics & Keywords

Phagocytosis and Immune Regulation Immune Cell Function and Interaction CAR-T cell therapy research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 379, Issue 18, pp. 1711-1721

DOI: 10.1056/nejmoa1807315

Field-Weighted Citation Impact: 43.84